Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
"Elanco Animal Health" Q2 2026 Earnings Call - Innovation Revenue Hits $340M, Raising Full-Year Guidance
Elanco Animal Health is proving that durable growth in animal health comes from a disciplined mix of innovation and commercial execution. Second quarter organic revenue climbed 8 percent, outpacing gu...
- Q2 organic constant currency revenue grew 8 percent, beating guidance and driven by double-digit gains in both U.S. pet health and U.S. farm animal segments.
- The Big Six innovation portfolio generated $340 million in revenue, prompting management to raise the full-year innovation target to $1.25 billion.
- Zenrelia officially reached blockbuster status, treating over 2.5 million dogs and penetrating more than 60 percent of U.S. clinics, with first-line usage exceeding 40 percent.
- +8 more takeaways
"Shake Shack" Q2 2026 Earnings Call - Beef Inflation Pressures Margins While Digital Growth and Record Unit Expansion Carry the Business
Shake Shack’s second quarter of 2026 reads like a masterclass in margin defense under siege. Record-high beef prices, up mid-teens, carved 90 basis points out of restaurant-level profitability, yet th...
- Record-high beef costs, up mid-teens and peaking in June, drove a 90 basis point restaurant margin decline, forcing management to prioritize traffic and value over full cost pass-through.
- Digital channels now represent 41% of total sales, with app transactions surging nearly 30% year-over-year and accounting for over 10% of the channel mix.
- Blended pricing rose 4.4% with approximately 1% taken in June, but 3.4% is rolling off through August and December, leaving room for surgical re-pricing if costs stay elevated.
- +7 more takeaways
"Circle" Q2 2026 Earnings Call - Decoupling from Crypto Volatility Through Regulated Infrastructure and Arc Launch
Circle’s second quarter marks a clean break from crypto-cycle dependency. USDC circulation averaged $76.5 billion, growing 19 percent year-over-year even as the broader digital asset market contracted...
- USDC circulation averaged $76.5 billion in Q2, up 19 percent year-over-year, effectively decoupling from a 40 percent contraction in broader digital asset market cap.
- Total revenue and reserve income reached $701 million, growing 7 percent year-over-year despite a 66 basis point decline in the reserve return rate to 3.48 percent.
- Adjusted EBITDA expanded 8 percent year-over-year to $143 million, delivering a disciplined 50 percent margin as the company shifts toward higher-margin platform services.
- +7 more takeaways
NCR Voyix Second Quarter 2026 Earnings Call - Recurring Revenue Hits 83% as VCP Adoption Accelerates and AI Slashes Deployment Costs
NCR Voyix is successfully pivoting away from lumpy hardware sales toward a predictable, subscription-driven model. Recurring revenue now accounts for 83% of total sales, with the new Voyix Commerce Pl...
- Recurring revenue now represents 83% of total sales, with the company actively phasing out one-time software licenses and professional services.
- The Voyix Commerce Platform signed 25 contracts in Q2, generating $286 million in remaining contract value, a 65% year-over-year increase.
- Ten enterprise customers are already live on the VCP across more than 2,000 lanes, with another 1,000 expected by late September.
- +9 more takeaways
"Uber" Q2 2026 Earnings Call - Record Cash Generation Fuels Delivery Hero Acquisition and AV Commercialization Push
Uber’s second quarter did not rely on event spikes or accounting tricks. Gross bookings cleared $58 billion, up 22 percent year over year, while trailing twelve month free cash flow topped $10 billion...
- Gross bookings surpassed $58 billion, marking a 22% year-over-year increase and beating the high end of guidance.
- Trailing twelve-month free cash flow exceeded $10 billion, enabling strategic capital deployment without compromising balance sheet health.
- Non-GAAP earnings per share grew 35% year-over-year, reflecting sustained operating leverage across mobility and delivery segments.
- +9 more takeaways
"COMPASS Pathways" Q2 2026 Earnings Call - Phase III Success Clears Regulatory Path for Q4 NDA and H1 2027 Launch
COMPASS Pathways has crossed the most dangerous stretch of the psychedelic drug development pipeline. Positive Phase III primary endpoints and 26-week durability data have effectively de-risked the cl...
- Phase III trials for COMP360 met primary endpoints with high statistical significance, confirming rapid antidepressant effects.
- 26-week durability data demonstrates clinically meaningful symptom reduction sustained for at least six months.
- Rolling FDA submission is underway, with management targeting a complete NDA filing in the fourth quarter of 2026.
- +7 more takeaways
The New York Times Company Q2 2026 Earnings Call - Digital Revenue Surges 16% as Video Bet and Direct Engagement Strategy Gain Traction
The New York Times delivered a quarter defined by disciplined execution and accelerating digital monetization. Digital subscription revenue climbed 16 percent to $408 million, adding 280,000 net subsc...
- Digital subscription revenue climbed 16 percent year-over-year to $408 million, adding 280,000 net new subscribers and pushing the digital-only base to 13.4 million.
- Digital advertising growth accelerated to 21 percent, outpacing guidance on strong marketer demand and high audience engagement across news, games, and sports.
- Adjusted operating profit jumped 16 percent to roughly $155 million, while adjusted diluted EPS rose 19 percent to $0.69.
- +9 more takeaways
Fresenius H1 2026 Q2 Earnings Call - Guidance Upgraded to 10-15% Core EPS Growth as Biopharma Scales and Cash Generation Accelerates
Fresenius is no longer asking the market to believe in a turnaround. The H1 2026 numbers prove it is already running. Core EPS jumped 14% at constant currency, group margins expanded by 60 basis point...
- Full-year core EPS guidance raised to 10-15% at constant currency, up from 5-10%, reflecting broad-based operational strength and improved earnings quality.
- Biopharma is the primary growth engine, posting 38% organic revenue growth in Q2 and scaling rapidly toward a 20% EBIT margin target by 2030.
- Group EBIT margin expanded 60 basis points to 12.3%, driven by operating leverage across Kabi and Helios without reliance on one-time items.
- +9 more takeaways
Acacia Research Corporation Q2 2026 Earnings Call - Fortress Balance Sheet and Episodic IP Licensing Drive Execution Amid Surging Private Equity Deal Flow
Acacia Research delivered a quarter defined by cash generation and strategic patience rather than linear earnings growth. Total revenue nearly doubled to $114.6 million, largely propelled by a single ...
- Acacia reported total revenue of $114.6 million in Q2 2026, nearly doubling the prior year, driven by a major Wi-Fi 6 licensing settlement.
- Operated segment adjusted EBITDA reached $22.8 million, while total company adjusted EBITDA came in at $17.3 million.
- The company maintains a fortress balance sheet with $334.6 million in cash, securities, and loans receivable and zero parent-level debt.
- +8 more takeaways
Geron Corporation Q2 2026 Earnings Call - RYTELO Revenue Grows 17% as Geron Targets Mid-to-High Full-Year Guidance
Geron Corporation delivered a quarter defined by commercial momentum and financial discipline. RYTELO net revenue climbed 17% to $57.5 million, driven by a third straight quarter of demand growth and ...
- RYTELO net revenue reached $57.5 million in Q2, marking a 17% year-over-year increase and the third consecutive quarter of demand expansion.
- Management projects full-year 2026 RYTELO net revenue to land at the mid-to-high end of the $220 million to $240 million guidance range.
- Operational leverage is evident. First-half operating expenses fell 4% while revenue surged 24%, underscoring the impact of the late-2025 workforce reduction.
- +8 more takeaways